Global PDE Inhibitors Market Introduction
Phosphodiesterase (PDE) inhibitors are therapeutic agents that target PDE isoenzymes and hinder the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate) therefore, prolonging the biological effect determined by the type of cell involved. Selective and non-selective PDE inhibitors are being discovered as possible treatments for a variety of indications such as Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), and other ailments. Phosphodiesterase super family is complex, large and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. Each of the phosphodiesterase families contains one or four genes. The phosphodiesterase are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and cytoskeleton.
Global PDE Inhibitors Market: Competitive Landscape
Founded in 1849, Pfizer, Inc. is based in New York, U.S. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, and infectious diseases. The company offers a wide range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups. Pfizer holds the leading position in the erectile dysfunction with its brand Viagra.
Need an Overview of the Report on PDE Inhibitors Market? Ask for the Brochure here
Eli Lilly and Company
Established in 1876, Eli Lilly and Company is located in Indianapolis, Indiana, U.S. It is a multinational pharmaceuticals organization, operating in more than 160 countries, with direct presence in 27 of them. The company primarily operates through three business segments: Pharmaceuticals, Animal Health, and Health Care Management Services. In the U.S., Eli Lilly and Company distributes human pharmaceutical products, principally through independent wholesale distributors, directly to pharmacies. Its human pharmaceutical products compete globally with products of many other companies in highly competitive markets.
Incorporated in 1863, Bayer is based in Leverkusen, Germany. It is a life sciences company, operating in pharmaceutical, consumer health, animal health, and agriculture domains with 150 years of history and core competences in the areas of health care and agriculture. Bayer is a group of 241 consolidated companies located in 79 countries across the world. Its consumer health segment maintains a global network of research & development facilities, with sites in the U.S., France, Germany, and China.
Founded in 2000, GlaxoSmithKline is based in Brentford, U.K. It is a global health care company, which is concentrated on three key business divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company has a product portfolio of established and innovative medicines. It has expertise in respiratory diseases, HIV, oncology, immune-inflammatory diseases, and rare diseases. GSK has worldwide presence in more than 150 countries, with 33% of its offices and centers in emerging markets.
Global PDE Inhibitors Market: Dynamics
Increase in Prevalence of Erectile Dysfunction to Drive PDE Inhibitors Market
The key factor driving the PDE inhibitors market is the increasing prevalence of erectile dysfunction. The etiology of erectile dysfunction can be ascribed to multiple factors, such as prostate cancer, hypertension, obesity, testosterone deficiency, diabetes mellitus, and hyperlipidemia. Furthermore, the consumption of certain substance abuse and medications can lead to erectile dysfunction. As most of the causes are related to lifestyle changes, the prevalence of erectile dysfunction is increasing globally. According to the World Health Organization (WHO), about 150 million people have been affected by erectile dysfunction and this is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.
Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “PDE Inhibitors Market” here
Increasing Burden of Chronic Diseases Expected to Fuel PDE Inhibitors Market
Chronic diseases such as stroke, chronic obstructive pulmonary disease, heart diseases, pre-diabetes, and diabetes are the leading causes of death. These diseases contribute to a considerable portion of annual health care expenditure. Increase in health care cost related to chronic diseases is expected to result in increased adoption of the PDE4 and PDE5 inhibitors. Therefore, an increase in the health related concerns and economic burden of these diseases is likely to increase the demand for PDE inhibitors which, in turn, is likely to promote the global PDE inhibitors market during the forecast period.
Global PDE Inhibitors Market: Segmentation
The global PDE inhibitors market can be segmented depending upon:
- Product Type
- Route of Administration
Global PDE Inhibitors Market Segmentation – By Product Type
Depending on product type, the global PDE inhibitors market can be classified into:
- PDE4 Inhibitors
- PDE5 Inhibitors
Global PDE Inhibitors Market Segmentation – By Route of Administration
In terms of route of administration, the global PDE inhibitors market can be divided into:
Global PDE Inhibitors Market Segmentation – By Application
Depending on the application, the global PDE inhibitors market can be segregated into:
- Erectile Dysfunction
- Chronic Obstructive Pulmonary Disease
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.